Weekly curation
What this week's longevity research found
Three recent studies on genetics and the brain, cellular mechanisms of aging, and results from a multidomain intervention.
This week's highlights
Polygenic scores for longevity and brain MRI measures in 70-year-olds
Original title: Polygenic scores for longevity in relation to brain MRI measures in a cohort of 70-year-olds
What the source reports
In a population-based sample of 675 70-year-olds in Sweden, genetic scores associated with longevity were not linked to MRI measures in the full group. Among men, the scores were associated with lower white matter lesion burden and small vessel disease, as well as greater thickness in some cortical regions.
Why it is worth following
The study examines how genetic propensity for longevity relates to aspects of brain health. Its results point to associations that differ by sex and brain region.
Evidence context and limitations
This was a cross-sectional observational analysis of people of similar ages in one Swedish cohort of European ancestry. Findings in men and specific cortical regions need replication; an association does not show that the scores cause brain protection.
Transcriptomic reprogramming screen identifies SRSF1 as a regulator of aging
What the source reports
A screen in human fibroblasts identified the RNA-processing factor SRSF1, which shifted some gene-expression signals toward a younger profile without erasing cell identity. In mice, inducible SRSF1 expression was associated with slower frailty progression and longer median survival.
Why it is worth following
The work offers an experimental lead for studying cellular processes involved in aging and frailty.
Evidence context and limitations
These are preclinical results from laboratory cells, worms, and mice; the mouse survival experiment had 9–10 animals per group. They do not show benefit or safety in people or justify treatment; some authors disclosed a patent application and company affiliations in this field.
Body weight after a multidomain lifestyle intervention in older adults at risk of dementia
Original title: Body weight following a multidomain lifestyle intervention in older adults at risk of dementia – A post-hoc analysis of the AgeWell.de-trial
What the source reports
In this post-hoc analysis of the AgeWell.de trial, 678 participants aged 60 to 77 with overweight or obesity were followed for 24 months. The intervention combined dietary guidance, physical, social, and cognitive activity, medication review, and other components. Assignment to the program was not associated with lower body weight at follow-up.
Why it is worth following
The result helps distinguish goals: a broad intervention targeting cognitive health does not necessarily lead to weight loss when that is not its primary focus.
Evidence context and limitations
Weight was assessed in a post-hoc analysis, not as the trial's primary outcome. Participants were at risk for dementia and recruited in Germany; this result does not show that lifestyle interventions in general fail to change body weight.